Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) has been assigned an average rating of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $2.9318.
HCAT has been the subject of several recent research reports. Wells Fargo & Company upped their price objective on Health Catalyst from $1.00 to $1.75 and gave the stock an “equal weight” rating in a research report on Friday, June 26th. Canaccord Genuity Group lifted their target price on Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Tuesday. Citigroup restated a “neutral” rating on shares of Health Catalyst in a research note on Thursday. Stephens decreased their price target on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Health Catalyst in a report on Wednesday, June 24th.
Get Our Latest Analysis on Health Catalyst
Health Catalyst Stock Up 3.5%
Health Catalyst (NASDAQ:HCAT – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of $0.01 by $0.01. The business had revenue of $70.76 million for the quarter, compared to analysts’ expectations of $69.24 million. Health Catalyst had a negative net margin of 87.69% and a negative return on equity of 3.52%. As a group, equities research analysts predict that Health Catalyst will post -0.25 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Health Catalyst
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HCAT. Focus Partners Wealth acquired a new position in shares of Health Catalyst during the 1st quarter worth about $46,000. nVerses Capital LLC acquired a new stake in shares of Health Catalyst in the fourth quarter valued at about $25,000. Cresset Asset Management LLC acquired a new stake in shares of Health Catalyst in the second quarter valued at about $39,000. FNY Investment Advisers LLC bought a new stake in Health Catalyst during the third quarter worth about $45,000. Finally, BNP Paribas Financial Markets raised its holdings in Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after acquiring an additional 6,832 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.
Health Catalyst Company Profile
Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.
The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.
Featured Stories
- Five stocks we like better than Health Catalyst
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
